KR101592609B1 - 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물 - Google Patents

소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR101592609B1
KR101592609B1 KR1020107013390A KR20107013390A KR101592609B1 KR 101592609 B1 KR101592609 B1 KR 101592609B1 KR 1020107013390 A KR1020107013390 A KR 1020107013390A KR 20107013390 A KR20107013390 A KR 20107013390A KR 101592609 B1 KR101592609 B1 KR 101592609B1
Authority
KR
South Korea
Prior art keywords
composition
active ingredient
insulin
buffer
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107013390A
Other languages
English (en)
Korean (ko)
Other versions
KR20100095449A (ko
Inventor
패리드 베니스
패리드 베니스
장-자크 세라노
Original Assignee
패리드 베니스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 패리드 베니스 filed Critical 패리드 베니스
Publication of KR20100095449A publication Critical patent/KR20100095449A/ko
Application granted granted Critical
Publication of KR101592609B1 publication Critical patent/KR101592609B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020107013390A 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물 Active KR101592609B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0759971 2007-12-19
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157032578A Division KR20150132887A (ko) 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20100095449A KR20100095449A (ko) 2010-08-30
KR101592609B1 true KR101592609B1 (ko) 2016-02-05

Family

ID=39671377

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107013390A Active KR101592609B1 (ko) 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물
KR1020157032578A Ceased KR20150132887A (ko) 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157032578A Ceased KR20150132887A (ko) 2007-12-19 2008-12-18 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물

Country Status (19)

Country Link
US (1) US8309123B2 (https=)
EP (1) EP2234598B1 (https=)
JP (1) JP5676272B2 (https=)
KR (2) KR101592609B1 (https=)
CN (1) CN101917967B (https=)
AP (1) AP3573A (https=)
AR (1) AR069847A1 (https=)
AU (1) AU2008345474B2 (https=)
BR (1) BRPI0821373B8 (https=)
CA (1) CA2709899C (https=)
EA (1) EA023107B1 (https=)
ES (1) ES3055634T3 (https=)
FR (1) FR2925333B1 (https=)
IL (1) IL206364A (https=)
MA (1) MA31927B1 (https=)
MX (1) MX2010006927A (https=)
TN (1) TN2010000290A1 (https=)
TW (1) TWI461226B (https=)
WO (1) WO2009083686A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2016014320A (es) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
EP3215128B1 (en) 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033531A1 (en) 1996-03-15 1997-09-18 Unigene Laboratories, Inc. Oral peptide pharmaceutical products
US20020132757A1 (en) 2000-05-15 2002-09-19 Mccoy Randall E. Formulations for administering calcitonin and processes for preparing the same
US20070154559A1 (en) 2003-12-24 2007-07-05 Chaul-Min Pai Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
WO2005113008A1 (en) * 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1773376A4 (en) * 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
PL1883394T3 (pl) 2005-05-23 2018-09-28 Sdg, Inc. Konstrukt lipidowy do dostarczania insuliny ssakowi
WO2007032018A1 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20070134332A1 (en) * 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033531A1 (en) 1996-03-15 1997-09-18 Unigene Laboratories, Inc. Oral peptide pharmaceutical products
US20020132757A1 (en) 2000-05-15 2002-09-19 Mccoy Randall E. Formulations for administering calcitonin and processes for preparing the same
US20070154559A1 (en) 2003-12-24 2007-07-05 Chaul-Min Pai Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof

Also Published As

Publication number Publication date
WO2009083686A9 (fr) 2009-10-15
HK1146386A1 (en) 2011-06-03
US20090176691A1 (en) 2009-07-09
KR20100095449A (ko) 2010-08-30
ES3055634T3 (en) 2026-02-13
MA31927B1 (fr) 2010-12-01
EP2234598C0 (fr) 2025-11-19
AP2010005298A0 (en) 2010-06-30
CN101917967A (zh) 2010-12-15
BRPI0821373B1 (pt) 2020-04-22
JP5676272B2 (ja) 2015-02-25
FR2925333A1 (fr) 2009-06-26
US8309123B2 (en) 2012-11-13
TWI461226B (zh) 2014-11-21
EA201070746A1 (ru) 2011-02-28
EP2234598A1 (fr) 2010-10-06
IL206364A0 (en) 2010-12-30
CA2709899A1 (fr) 2009-07-09
FR2925333B1 (fr) 2012-04-13
TN2010000290A1 (fr) 2011-11-11
AU2008345474A1 (en) 2009-07-09
TW200940107A (en) 2009-10-01
IL206364A (en) 2016-12-29
CA2709899C (fr) 2018-01-16
BRPI0821373B8 (pt) 2021-05-25
EP2234598B1 (fr) 2025-11-19
AU2008345474B2 (en) 2014-07-31
EA023107B1 (ru) 2016-04-29
WO2009083686A1 (fr) 2009-07-09
BRPI0821373A2 (pt) 2015-06-16
AR069847A1 (es) 2010-02-24
MX2010006927A (es) 2010-12-06
JP2011506587A (ja) 2011-03-03
CN101917967B (zh) 2013-05-22
AP3573A (en) 2016-02-08
KR20150132887A (ko) 2015-11-26

Similar Documents

Publication Publication Date Title
KR101592609B1 (ko) 소화 효소로부터 보호되는 적어도 하나의 단백질 활성 성분을 함유하는 약학적 조성물
Arbit et al. Oral insulin: the rationale for this approach and current developments
US20040018190A1 (en) Drugs and foods improving the quality of life and process for producing the same
EP1624882A2 (en) Compositions for delivering peptide yy and pyy agonists
JP2017061572A (ja) Ｒａの処置のためのカルシトニンの使用
EP4122483A1 (en) Oral pharmaceutical composition
JP2006515620A (ja) 夜間の経口インスリン治療
WO2023123063A1 (en) Oral delivery
WO2018185669A1 (en) Effervescent compositions comprising saxagliptin or salt thereof
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂
US20130090288A1 (en) Pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes
KR102932912B1 (ko) 역마이셀 약물 전달체 및 이를 포함하는 경구용 약학적 조성물
HK1146386B (en) Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
US20250152721A1 (en) Pharmaceutical composition containing pegylated exenatide variant and use thereof
WO2023017537A1 (en) Oral algal oil based gastro-intestinal tract permeable peptide composition
EA051594B1 (ru) Фармацевтическая композиция, содержащая пегилированный вариант эксенатида, и ее применение
WO2022035400A1 (en) A tablet formulation comprising sitagliptin and metformi̇n

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100617

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131014

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141208

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150716

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141208

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20151015

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150716

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20151201

Appeal identifier: 2015101006050

Request date: 20151015

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151113

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20151113

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20151015

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20150306

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20100721

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20151201

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20151120

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160201

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190201

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190201

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200519

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200519

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20210520

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20210520

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20220121

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20220121

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230724

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240124

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20250203

Start annual number: 10

End annual number: 10